Lurbinectedin, a selective inhibitor of oncogenic transcription, in patients with pretreated germline BRCA1/2 metastatic breast cancer: results from a phase II basket study

•Loss of function due to mutations in the breast cancer gene, BRCA, leads to worse prognosis in breast cancer patients.•Lurbinectedin has previously shown antitumor activity in breast cancer patients with mutations in BRCA2.•This phase II basket study included a cohort of 21 patients with BRCA-mutated breast cancer treated with lurbinectedin.•The study showed antitumor activity and supports further investigation in this type of cancer.